Literature DB >> 23523538

Diabetic severity and risk of kidney stone disease.

Aviva E Weinberg1, Chirag J Patel, Glenn M Chertow, John T Leppert.   

Abstract

BACKGROUND: The prevalence of kidney stone disease is rising along with increasing rates of obesity, type 2 diabetes mellitus (T2DM), and metabolic syndrome.
OBJECTIVE: To investigate the associations among the presence and severity of T2DM, glycemic control, and insulin resistance with kidney stone disease. DESIGN, SETTING, AND PARTICIPANTS: We performed a cross-sectional analysis of all adult participants in the 2007-2010 National Health and Nutrition Examination Survey (NHANES). A history of kidney stone disease was obtained by self-report. T2DM was defined by self-reported history, T2DM-related medication usage, and reported diabetic comorbidity. Insulin resistance was estimated using fasting plasma insulin (FPI) levels and the homeostasis model assessment of insulin resistance (HOMA-IR) definition. We classified glycemic control using glycosylated hemoglobin A1c (HbA1c) and fasting plasma-glucose levels (FPG). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Odds ratios (OR) for having kidney stone disease were calculated for each individual measure of T2DM severity. Logistic regression models were fitted adjusting for age, sex, race/ethnicity, smoking history, and the Quételet index (body mass index), as well as laboratory values and components of metabolic syndrome. RESULTS AND LIMITATIONS: Correlates of kidney stone disease included a self-reported history of T2DM (OR: 2.44; 95% confidence interval [CI], 1.84-3.25) and history of insulin use (OR: 3.31; 95% CI, 2.02-5.45). Persons with FPG levels 100-126 mg/dl and >126 mg/dl had increased odds of having kidney stone disease (OR 1.28; 95% CI, 0.95-1.72; and OR 2.29; 95% CI, 1.68-3.12, respectively). Corresponding results for persons with HbA1c 5.7-6.4% and ≥ 6.5% were OR 1.68 (95% CI, 1.17-2.42) and OR 2.82 (95% CI, 1.98-4.02), respectively. When adjusting for patient factors, a history of T2DM, the use of insulin, FPI, and HbA1c remained significantly associated with kidney stone disease. The cross-sectional design limits causal inference.
CONCLUSIONS: Among persons with T2DM, more-severe disease is associated with a heightened risk of kidney stones.
Copyright © 2013 European Association of Urology. All rights reserved.

Entities:  

Keywords:  Diabetes mellitus; Glycemic control; Insulin resistance; Kidney stone disease

Mesh:

Substances:

Year:  2013        PMID: 23523538      PMCID: PMC3866968          DOI: 10.1016/j.eururo.2013.03.026

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  25 in total

1.  Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis.

Authors:  Mary Ann Cameron; Naim M Maalouf; Beverley Adams-Huet; Orson W Moe; Khashayar Sakhaee
Journal:  J Am Soc Nephrol       Date:  2006-04-05       Impact factor: 10.121

2.  Obesity, weight gain, and the risk of kidney stones.

Authors:  Eric N Taylor; Meir J Stampfer; Gary C Curhan
Journal:  JAMA       Date:  2005-01-26       Impact factor: 56.272

3.  Prevalence of kidney stones in the United States.

Authors:  Charles D Scales; Alexandria C Smith; Janet M Hanley; Christopher S Saigal
Journal:  Eur Urol       Date:  2012-03-31       Impact factor: 20.096

4.  Renal hypouricaemia in insulin treated diabetes mellitus.

Authors:  A Gotfredsen; P McNair; C Christiansen; I Transbøl
Journal:  Clin Chim Acta       Date:  1982-04-23       Impact factor: 3.786

5.  Pathophysiologic basis for normouricosuric uric acid nephrolithiasis.

Authors:  Khashayar Sakhaee; Beverley Adams-Huet; Orson W Moe; Charles Y C Pak
Journal:  Kidney Int       Date:  2002-09       Impact factor: 10.612

6.  Serum uric acid, serum glucose and diabetes: relationships in a population study.

Authors:  D G Cook; A G Shaper; D S Thelle; T P Whitehead
Journal:  Postgrad Med J       Date:  1986-11       Impact factor: 2.401

Review 7.  Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association.

Authors:  Jay S Skyler; Richard Bergenstal; Robert O Bonow; John Buse; Prakash Deedwania; Edwin A M Gale; Barbara V Howard; M Sue Kirkman; Mikhail Kosiborod; Peter Reaven; Robert S Sherwin
Journal:  J Am Coll Cardiol       Date:  2009-01-20       Impact factor: 24.094

Review 8.  Economics and cost of care of stone disease.

Authors:  Yair Lotan
Journal:  Adv Chronic Kidney Dis       Date:  2009-01       Impact factor: 3.620

Review 9.  Targets and tactics: the relative importance of HbA, fasting and postprandial plasma glucose levels to glycaemic control in type 2 diabetes.

Authors:  V Woo; M V Shestakova; C Ørskov; A Ceriello
Journal:  Int J Clin Pract       Date:  2008-12       Impact factor: 2.503

10.  Glyoxal formation and its role in endogenous oxalate synthesis.

Authors:  Jessica N Lange; Kyle D Wood; John Knight; Dean G Assimos; Ross P Holmes
Journal:  Adv Urol       Date:  2012-04-08
View more
  31 in total

1.  Diabetes mellitus and the risk of urolithiasis: a meta-analysis of observational studies.

Authors:  Lu Hao Liu; Ran Kang; Jun He; Shan Kun Zhao; Fu Tian Li; Zhi Gang Zhao
Journal:  Urolithiasis       Date:  2015-04-17       Impact factor: 3.436

2.  Risk of ESRD and Mortality in Kidney and Bladder Stone Formers.

Authors:  Tsering Dhondup; Wonngarm Kittanamongkolchai; Lisa E Vaughan; Ramila A Mehta; Jasdeep K Chhina; Felicity T Enders; LaTonya J Hickson; John C Lieske; Andrew D Rule
Journal:  Am J Kidney Dis       Date:  2018-08-23       Impact factor: 8.860

3.  Effect of indwelling time of double J tube on infected ureteral calculi and the distribution of pathogenic characteristics in diabetics.

Authors:  Wenxian Xie; Suchuan Zhang; Xiaobin Li; Yuejiang Liu; Jian Yang; Ping Liu; Ke Zeng
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

4.  Physical Activity Reduces the Effect of High Body Mass Index on Kidney Stones in Diabetes Participants From the 2007-2018 NHANES Cycles: A Cross-Sectional Study.

Authors:  Weipu Mao; Lei Zhang; Si Sun; Jianping Wu; Xiangyu Zou; Guangyuan Zhang; Ming Chen
Journal:  Front Public Health       Date:  2022-07-01

5.  Metabolic Syndrome and Nephrolithiasis Risk: Should the Medical Management of Nephrolithiasis Include the Treatment of Metabolic Syndrome?

Authors:  John Michael DiBianco; T W Jarrett; Patrick Mufarrij
Journal:  Rev Urol       Date:  2015

6.  Sex Differences in Kidney Stone Disease in Chinese Patients with Type 2 Diabetes Mellitus.

Authors:  Ying Xiao; Ling Wei; Xiaofen Xiong; Yuan Yang; Li Li; Ming Yang; Fei Deng; Lin Sun
Journal:  Kidney Dis (Basel)       Date:  2020-02-28

7.  Do Hypertension, diabetes mellitus and obesity increase the risk of severity of nephrolithiasis?

Authors:  Eyup Burak Sancak; Mustafa Reşorlu; Alpaslan Akbas; Murat Tolga Gulpinar; Muhammet Arslan; Berkan Resorlu
Journal:  Pak J Med Sci       Date:  2015       Impact factor: 1.088

8.  Analysis of altered microRNA expression profiles in proximal renal tubular cells in response to calcium oxalate monohydrate crystal adhesion: implications for kidney stone disease.

Authors:  Bohan Wang; Bolin Wu; Jun Liu; Weimin Yao; Ding Xia; Lu Li; Zhiqiang Chen; Zhangqun Ye; Xiao Yu
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

9.  50 week ultrasound imaging and ultrastructural abnormalities of bladder after sugar diuresis and diabetes mellitus in rats.

Authors:  Kexun Yang; Qinzhang Wang
Journal:  Int Urol Nephrol       Date:  2021-06-10       Impact factor: 2.370

10.  Increased risk of acute coronary syndrome among patients with urinary stone disease: a nationwide population-based cohort study.

Authors:  Shun-Fa Hung; Chao-Yuan Huang; Cheng-Li Lin; Shiu-Dong Chung; Chi-Jung Chung; Chia-Hung Kao; Chao-Hsiang Chang
Journal:  PLoS One       Date:  2014-07-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.